Literature DB >> 31576328

Looking beyond cancer for cabozantinib-induced cardiotoxicity: evidence of absence or absence of evidence?

Eugenia Y Lee1, Andrew T Yan1,2.   

Abstract

Entities:  

Year:  2019        PMID： 31576328      PMCID： PMC6685911          DOI： 10.21037/atm.2019.05.51

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

1.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

2.  Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.

Authors:  Roberto Iacovelli; Chiara Ciccarese; Giuseppe Fornarini; Francesco Massari; Davide Bimbatti; Claudia Mosillo; Sara Elena Rebuzzi; Vincenzo Di Nunno; Massimiliano Grassi; Emanuela Fantinel; Andrea Ardizzoni; Giampaolo Tortora
Journal:  Br J Clin Pharmacol       Date:  2019-03-31       Impact factor: 4.335

3.  Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.

Authors:  Edith Pituskin; John R Mackey; Sheri Koshman; Davinder Jassal; Marshall Pitz; Mark J Haykowsky; Joseph J Pagano; Kelvin Chow; Richard B Thompson; Larissa J Vos; Sunita Ghosh; Gavin Y Oudit; Justin A Ezekowitz; D Ian Paterson
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

Review 4.  Assessment of Left Ventricular Function by Echocardiography: The Case for Routinely Adding Global Longitudinal Strain to Ejection Fraction.

Authors:  Elizabeth Potter; Thomas H Marwick
Journal:  JACC Cardiovasc Imaging       Date:  2018-02

5.  A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.

Authors:  M S Ewer; M K Ali; B Mackay; S Wallace; M Valdivieso; S S Legha; R S Benjamin; T P Haynie
Journal:  J Clin Oncol       Date:  1984-02       Impact factor: 44.544

6.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Authors:  Ghassan K Abou-Alfa; Tim Meyer; Ann-Lii Cheng; Anthony B El-Khoueiry; Lorenza Rimassa; Baek-Yeol Ryoo; Irfan Cicin; Philippe Merle; YenHsun Chen; Joong-Won Park; Jean-Frederic Blanc; Luigi Bolondi; Heinz-Josef Klümpen; Stephen L Chan; Vittorina Zagonel; Tiziana Pressiani; Min-Hee Ryu; Alan P Venook; Colin Hessel; Anne E Borgman-Hagey; Gisela Schwab; Robin K Kelley
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

7.  Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Authors:  Daniela Cardinale; Alessandro Colombo; Maria T Sandri; Giuseppina Lamantia; Nicola Colombo; Maurizio Civelli; Giovanni Martinelli; Fabrizio Veglia; Cesare Fiorentini; Carlo M Cipolla
Journal:  Circulation       Date:  2006-11-13       Impact factor: 29.690

8.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).

Authors:  Xavier Bosch; Montserrat Rovira; Marta Sitges; Ariadna Domènech; José T Ortiz-Pérez; Teresa M de Caralt; Manuel Morales-Ruiz; Rosario J Perea; Mariano Monzó; Jordi Esteve
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

Review 9.  Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.

Authors:  Sean A Virani; Susan Dent; Christine Brezden-Masley; Brian Clarke; Margot K Davis; Davinder S Jassal; Christopher Johnson; Julie Lemieux; Ian Paterson; Igal A Sebag; Christine Simmons; Jeffrey Sulpher; Kishore Thain; Paaldinesh Thavendiranathan; Jason R Wentzell; Nola Wurtele; Marc André Côté; Nowell M Fine; Haissam Haddad; Bradley D Hayley; Sean Hopkins; Anil A Joy; Daniel Rayson; Ellamae Stadnick; Lynn Straatman
Journal:  Can J Cardiol       Date:  2016-04-07       Impact factor: 5.223

Review 10.  Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.

Authors:  Stephen J H Dobbin; Alan C Cameron; Mark C Petrie; Robert J Jones; Rhian M Touyz; Ninian N Lang
Journal:  Heart       Date:  2018-09-18       Impact factor: 5.994
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.